MX2020001757A - Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. - Google Patents

Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.

Info

Publication number
MX2020001757A
MX2020001757A MX2020001757A MX2020001757A MX2020001757A MX 2020001757 A MX2020001757 A MX 2020001757A MX 2020001757 A MX2020001757 A MX 2020001757A MX 2020001757 A MX2020001757 A MX 2020001757A MX 2020001757 A MX2020001757 A MX 2020001757A
Authority
MX
Mexico
Prior art keywords
diseases
compounds
salts
treatment
methods
Prior art date
Application number
MX2020001757A
Other languages
English (en)
Spanish (es)
Inventor
Roger Olsson
Ethan S Burstein
Björn Gustav Borgström
Karl Erik Jansson
Niklas Patrik Sköld
Wachenfeldt Henrik Von
Larisa Yudina Wahlström
Original Assignee
Acadia Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acadia Pharm Inc filed Critical Acadia Pharm Inc
Publication of MX2020001757A publication Critical patent/MX2020001757A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020001757A 2017-08-21 2018-08-20 Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades. MX2020001757A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762548301P 2017-08-21 2017-08-21
SE1730225 2017-08-24
PCT/US2018/000354 WO2019040107A1 (en) 2017-08-21 2018-08-20 COMPOUNDS, CORRESPONDING SALTS AND METHODS FOR THE TREATMENT OF DISEASES

Publications (1)

Publication Number Publication Date
MX2020001757A true MX2020001757A (es) 2020-09-07

Family

ID=63840976

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020001757A MX2020001757A (es) 2017-08-21 2018-08-20 Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.

Country Status (22)

Country Link
US (3) US11345693B2 (https=)
EP (2) EP3672954B1 (https=)
JP (2) JP7297738B2 (https=)
KR (1) KR102692233B1 (https=)
CN (2) CN117466803A (https=)
AU (1) AU2018321546B2 (https=)
BR (1) BR112020003477A2 (https=)
CA (1) CA3071644A1 (https=)
DK (1) DK3672954T3 (https=)
ES (1) ES3042110T3 (https=)
FI (1) FI3672954T3 (https=)
HU (1) HUE073569T2 (https=)
IL (1) IL272444B (https=)
LT (1) LT3672954T (https=)
MX (1) MX2020001757A (https=)
PL (1) PL3672954T3 (https=)
PT (1) PT3672954T (https=)
RS (1) RS67273B1 (https=)
SG (1) SG11202001062XA (https=)
SI (1) SI3672954T1 (https=)
WO (1) WO2019040107A1 (https=)
ZA (1) ZA202001717B (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3672960A2 (en) 2017-08-21 2020-07-01 Acadia Pharmaceuticals Inc. Compounds, salts thereof and their use for the treatment of diseases
MX2020001757A (es) * 2017-08-21 2020-09-07 Acadia Pharm Inc Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
ES2906868T3 (es) * 2019-05-22 2022-04-20 Zakl Farmaceutyczne Polpharma S A Intermedio farmacéutico para preparar pimavanserina
WO2020249117A1 (zh) * 2019-06-12 2020-12-17 华东理工大学 抗高血压的多元醇化合物及其衍生物
CN113214231B (zh) * 2020-01-21 2022-04-08 瀚远医药有限公司 5ht2a受体拮抗剂及其医疗应用
CN115677723B (zh) * 2020-01-21 2024-06-04 瀚远医药有限公司 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
WO2021147818A1 (zh) * 2020-01-21 2021-07-29 瀚远医药有限公司 5-ht2a受体拮抗剂及其治疗中枢神经系统疾病的应用
CN113214141B (zh) * 2020-01-21 2022-04-08 瀚远医药有限公司 5ht2a受体拮抗剂及其制备和应用
US12527775B2 (en) 2020-03-26 2026-01-20 Shionogi & Co., Ltd. Heteroaromatic derivatives having serotonin receptor binding activity
CN111548257B (zh) * 2020-05-28 2022-11-15 安道麦马克西姆有限公司 一种（4-异丙氧基-2-甲基）苯基异丙基酮的制备方法
CN114728933B (zh) * 2020-07-22 2023-06-16 山东绿叶制药有限公司 5-ht2a受体抑制剂或反向激动剂及其制备方法和应用
JP7741820B2 (ja) * 2020-12-28 2025-09-18 塩野義製薬株式会社 セロトニン受容体結合活性を有する環状アミン誘導体
CN113292484B (zh) * 2021-06-04 2022-11-15 沈阳药科大学 3-(4-甲基哌啶-1-基)-3-苄基脲类化合物及其类似物、制备方法及应用
CA3228653A1 (en) * 2021-08-11 2023-02-16 Monali BANERJEE Small molecule urea derivatives as sting antagonists
EP4570793A1 (en) * 2022-08-03 2025-06-18 Luye Innomind Pharma Shijiazhuang Co., Ltd. 5-ht2a receptor inverse agonist, and preparation method therefor and use thereof
WO2024067304A1 (zh) * 2022-09-28 2024-04-04 瀚远医药有限公司 一种具有Sigma2和5HT2A抑制活性的化合物及用途
WO2024105007A1 (en) * 2022-11-15 2024-05-23 Samsara Therapeutics Inc. Autophagy inducing compounds and uses thereof
WO2025029990A1 (en) 2023-08-02 2025-02-06 Acadia Pharmaceuticals Inc. 3-(4-cyclo-propoxybenzyl)-1-(2,4-difluorobenzyl)-1 -(1-methylpiperidin-4-yl)urea for use in the treatment of diseases associated with the serotonin-receptor 5-ht
WO2025162237A1 (zh) * 2024-02-02 2025-08-07 绿叶嘉奥制药石家庄有限公司 一种5-ht2a受体反向激动剂的盐型、晶型及其制备方法和应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1998A (en) 1841-03-12 Refrigerator
IL110298A (en) 1993-07-13 1999-04-11 Brann Mark Robert Identification of ligands by selective amplification of cells transfected with receptors
FR2802206B1 (fr) * 1999-12-14 2005-04-22 Sod Conseils Rech Applic Derives de 4-aminopiperidine et leur utilisation en tant que medicament
ES2278729T3 (es) 2000-03-06 2007-08-16 Acadia Pharmaceuticals Inc. Compuestos azaciclicos para usar en el tratamiento de enfermedades relacionadas con la serotonina.
GB0108099D0 (en) * 2001-03-30 2001-05-23 Hoffmann La Roche Aminopiperidine derivatives
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
EP1562937A2 (en) * 2002-06-24 2005-08-17 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
DK2009000T3 (da) 2003-01-16 2011-09-05 Acadia Pharm Inc Selektive serotonin 2A/2C-receptor invers-agonister som terapeutika for neurodegenerative sygdomme
CA2580129A1 (en) 2004-09-27 2006-04-06 Acadia Pharmaceuticals Inc. Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-n'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation
US7790899B2 (en) * 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
GT200600042A (es) 2005-02-10 2006-09-27 Aventis Pharma Inc Compuestos de bis arilo y heteroarilo sustituido como antagonistas selectivos de 5ht2a
CA2630860A1 (en) * 2005-11-25 2007-05-31 Galapagos Sas Urea derivatives useful as calcium receptor modulators
TW200831517A (en) 2006-12-15 2008-08-01 Astrazeneca Ab Chemical compounds
WO2008141057A1 (en) * 2007-05-08 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated pimavanserin 1- (4-flu0r0benzyl) -3- (4-isobutoxybenzyl) -1- ( l-methyl-piperidin-4-yl) -urea
KR100878446B1 (ko) 2007-06-07 2009-01-13 일동제약주식회사 신규 펩티드 데포르밀라제 저해제 화합물 및 그 제조방법
JP2010540454A (ja) 2007-09-21 2010-12-24 アカディア ファーマシューティカルズ，インコーポレーテッド ピマバンセリンと他の薬剤との併用投与
CA2700332A1 (en) * 2007-09-21 2009-03-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2010111353A1 (en) * 2009-03-25 2010-09-30 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
WO2012113103A1 (en) 2011-02-25 2012-08-30 Helsinn Healthcare S.A. Asymmetric ureas and medical uses thereof
SG11201605757SA (en) 2013-12-20 2016-08-30 Inst Drug Discovery Substituted amino triazoles, and methods using same
CN104844502B (zh) 2015-06-05 2018-07-31 齐鲁师范学院 一种匹莫范色林的制备方法
ES2890492T3 (es) 2015-07-20 2022-01-20 Acadia Pharm Inc Métodos para preparar N-(4-fluorobencil)-N-(1-metilpiperidin-4-il)-N'-(4-(2-metilpropiloxi)fenilmetil)carbamida y su sal de tartrato y forma polimórfica C
CN105481757A (zh) 2015-12-25 2016-04-13 北京康立生医药技术开发有限公司 一种哌马色林的制备方法
MX2020001757A (es) 2017-08-21 2020-09-07 Acadia Pharm Inc Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
EP3672960A2 (en) 2017-08-21 2020-07-01 Acadia Pharmaceuticals Inc. Compounds, salts thereof and their use for the treatment of diseases

Also Published As

Publication number Publication date
RS67273B1 (sr) 2025-10-31
ES3042110T3 (en) 2025-11-18
JP2020531505A (ja) 2020-11-05
SG11202001062XA (en) 2020-03-30
CN117466803A (zh) 2024-01-30
US20220298151A1 (en) 2022-09-22
US20200270239A1 (en) 2020-08-27
EP4635568A3 (en) 2025-12-03
PL3672954T3 (pl) 2025-11-12
US20250197385A1 (en) 2025-06-19
CA3071644A1 (en) 2019-02-28
JP2023116691A (ja) 2023-08-22
SI3672954T1 (sl) 2025-11-28
IL272444B (en) 2021-12-01
AU2018321546B2 (en) 2022-09-08
PT3672954T (pt) 2025-09-29
NZ761678A (en) 2025-05-30
LT3672954T (lt) 2025-10-27
DK3672954T3 (da) 2025-10-20
HUE073569T2 (hu) 2026-01-28
KR102692233B1 (ko) 2024-08-05
FI3672954T3 (fi) 2025-10-16
JP7628578B2 (ja) 2025-02-10
IL272444A (en) 2020-03-31
EP3672954B1 (en) 2025-08-13
BR112020003477A2 (pt) 2020-08-25
CN111132976A (zh) 2020-05-08
US12139477B2 (en) 2024-11-12
EP3672954A1 (en) 2020-07-01
JP7297738B2 (ja) 2023-06-26
KR20200043409A (ko) 2020-04-27
WO2019040107A1 (en) 2019-02-28
CN111132976B (zh) 2023-08-22
EP4635568A2 (en) 2025-10-22
ZA202001717B (en) 2025-04-30
AU2018321546A1 (en) 2020-02-27
US11345693B2 (en) 2022-05-31

Similar Documents

Publication Publication Date Title
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
ECSP19052302A (es) Derivados de benzooxazol como inmunomoduladores
EA201890308A1 (ru) Замещенные азасоединения как ингибиторы irak-4
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
CO2018007528A2 (es) Compuestos heterocíclicos como inmunomoduladores
NI201600165A (es) Inhibidores de desmetilasa 1 específica a lisina
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
MX382671B (es) Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
MX374605B (es) Compuestos inhibidores de jak quinasa para el tratamiento de enfermedad respiratoria.
CO2017003838A2 (es) Compuestos de aminopurina sustituida, composiciones del mismo, y métodos de tratamiento con los mismos
MX2018002889A (es) Compuesto de pirimidina fusionada o sal del mismo.
EA201990833A1 (ru) Соединение пиридина
CL2021000292A1 (es) Benzimidazoles sustituidos como inhibidores de pad4.
DOP2016000308A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
EA202091731A1 (ru) Ингибиторы аутотаксина и их применения
MX2019003026A (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2.
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
UY35274A (es) Compuestos y métodos para tratar infecciones bacterianas
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
CO2017001523A2 (es) Novedosas pirimidinas 2,5-sustituidas
MX2017015926A (es) Uso de derivados de bencimidazol para escape acido nocturno.